Anixa Biosciences Inc. has announced the initiation of dosing in the fourth cohort of its ongoing Phase 1 clinical trial for a novel CAR-T therapy targeting recurrent ovarian cancer. This cohort will receive a dose of three million CAR-positive cells per kilogram, which is thirty times higher than the initial dose administered in the first cohort. The trial, conducted in partnership with Moffitt Cancer Center, aims to evaluate the safety and therapeutic potential of this treatment. No dose-limiting toxicities were observed in the previous cohort, allowing the progression to this higher dose. The study is currently focused on safety and determining the maximum tolerated dose, with promising early signs of potential efficacy. Results from this study are yet to be presented.